- $1.79bn
- $1.87bn
- $109.79m
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors
Brief: UroGen receives FDA agreement on NDA submission strategy in Recurrent LG-IR-NMIBC based on UTOPIA Trial
Brief: UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule
Brief: UroGen Reports 72.2% 24-Month Response in Phase 3 Trial of FDA-Approved Zusduri
UroGen Pharma rises on FDA approval for bladder cancer drug
Brief: Urogen Pharma Says Zusduri Expected To Be Available In U.S. By July 1
US FDA approves UroGen's bladder cancer drug (updated)
Brief: FDA Approves Mitomycin Intravesical Solution For Bladder Cancer
US FDA approves Urogen's bladder cancer drug
UroGen Pharma falls as FDA panel narrowly votes against bladder cancer drug
UroGen Pharma falls as FDA panel narrowly votes against bladder cancer drug
Brief: Urogen Announces FDA Advisory Committee For Ugn-102, An Investigational Treatment For Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Brief: Urogen Announces Updated 18-Month Duration Of Response (Dor) Of 80.6% From The Phase 3 Envision Trial Of Ugn-102
U.S. STOCKS ON THE MOVE-Grocery Outlet, Abbott, General Dynamics
Brokerages see potential in UroGen's experimental bladder cancer drug
UroGen Pharma falls on wider-than-expected Q4 loss